China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a Phase III clinical study for its allogeneic human adipose mesenchymal progenitor cell injection, AlloJoin. This follows a successful randomized, double-blind, controlled multi-center Phase II clinical study, which included a 96-week follow-up and preliminarily demonstrated a favorable safety and efficacy profile for AlloJoin in treating knee osteoarthritis (KOA).
Positive Phase II Results Highlight AlloJoin’s Efficacy
The Phase II study indicated that AlloJoin significantly improved knee pain and function in subjects, while also delaying articular cartilage wear and enhancing the overall quality of life for patients. These promising results have paved the way for the Phase III study, marking a significant advancement in the development of stem cell therapies for KOA.
AlloJoin: A Milestone in Stem Cell Therapy in China
AlloJoin is notable for being the first stem cell product to enter the Phase II clinical trial stage in China, and it is also the first of its kind to commence a Phase III study specifically for knee osteoarthritis. This positions Cellular Biomedicine Group at the forefront of innovative treatments in the rapidly evolving field of regenerative medicine.-Fineline Info & Tech
